Our Faculty

Flavio Guzmán, M.D.

Flavio Guzmán, M.D.

Editor & CEO
Psychopharmacology Institute

Biography

No biography found.

Publications of Flavio Guzmán, M.D.

Revisão do primeiro trimestre de 2026: milsaperidona, agonistas do receptor GLP-1 e zuranolona

0,50 CMEs
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA's removal of the GLP-1 suicidality warning mean for your practice? How does ACOG's updated guidance position zuranolone for severe postpartum depression?
Flavio Guzmán, M.D.
Psychopharmacology Institute
View more info

Guia da venlafaxina: farmacologia, indicações, diretrizes de dosagem e efeitos adversos

0,50 CMEs
This guide covers pharmacodynamics, pharmacokinetics, dosage forms, indications, side effects, and use in special populations. It also discusses venlafaxine's mechanism of action, metabolism, and FDA-approved and off-label uses.
Flavio Guzmán, M.D.
Psychopharmacology Institute
View more info

Citalopram e escitalopram: resumo das principais diferenças e semelhanças

0,50 CMEs
This article provides an in-depth comparison of citalopram and escitalopram, covering their chemical composition, pharmacokinetics, FDA-approved indications, off-label uses, potential side effects, and the risk of QT prolongation associated with both drugs. Furthermore, it addresses crucial considerations for prescribing these medications to specific patient populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
View more info

Guia prático da fluoxetina: farmacologia, indicações, diretrizes de dosagem e efeitos adversos

0,50 CMEs
Fluoxetine is a potent serotonin reuptake inhibitor with a long half-life. It is FDA-approved for depression, OCD, panic disorder and bulimia. Fluoxetine also has off-label uses like treating repetitive behaviors in autism. This guide covers fluoxetine's pharmacology, dosing, side effects and use in special populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
View more info

Guia prático da fluvoxamina: farmacologia, indicações, diretrizes de dosagem e efeitos adversos

0,50 CMEs
Fluvoxamine (Luvox) is approved for OCD in both pediatric and adult patients in the U.S. There is no definitive evidence suggesting it is more effective than other SSRIs for OCD. It is also approved for depression in the UK. Fluvoxamine is an inhibitor of CYP1A2 and should not be combined with MAOIs.
Flavio Guzmán, M.D.
Psychopharmacology Institute
View more info

Explore our library of over 440 video lectures, podcasts, research summaries and expert interviews.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.